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Here we report the NMR solution structures of Mycobacterium 
tuberculosis (M. tuberculosis) thioredoxin C in both oxidized and reduced 
states, with discussion of structural changes that occur in going between 
redox states. The NMR solution structure of the oxidized TrxC corresponds 
closely to that of the crystal structure, except in the C-terminal region. It 
appears that crystal packing effects have caused an artifactual shift in the α4 
helix in the previously reported crystal structure, compared to the solution 
structure. Based on these TrxC structures, chemical shift mapping, a 
previously reported crystal structure of the M. tuberculosis thioredoxin 
reductase (not bound to a Trx) and structures for intermediates in the E. coli 
thioredoxin catalytic cycle, we have modeled the complete M. tuberculosis 
thioredoxin system for the various steps in the catalytic cycle. These 
structures and models reveal pockets at the TrxR/TrxC interface in various 
steps in the catalytic cycle, which can be targeted in the design of 
uncompetitive inhibitors as potential anti-mycobacterial agents, or as 
chemical genetic probes of function. 
Keywords: Thioredoxin, Thioredoxin reductase, Mycobacterium tuberculosis, 
NMR, solution structure. 
Introduction 
Mycobacterium tuberculosis (M. tuberculosis) is the causative 
agent of tuberculosis, which has a mortality rate of 1.3 million people 
in 2008.1 It is estimated that a third of the world population is infected 
with a latent form of M. tuberculosis.2 The M. tuberculosis pathogen 
resides in the alveolar phagocytes of the host and can resist the 
oxidative killing of these immune cells, but the exact mechanism of 
this resistance is remains unclear.3 Disrupting this defense could be an 
effective means by which that pathogen could be killed, so the proteins 
involved in this defense are being pursued as potential targets for new 
anti-mycobacterial drugs. The method by which host phagocytes 
attempt to kill the invading M. tuberculosis pathogen is via production 
of reactive oxygen and nitrogen species, including superoxides and 
hydrogen peroxide, which can be toxic to the microbe.4 One method 
that M. tuberculosis uses to resist this oxidative attack is via the same 
process that eukaryotic cells use to combat oxidative stress, using the 
thiol reductants of the thioredoxin system (in addition to other 
enzymatic anti-oxidant systems). In other prokaryotic organisms, the 
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thioredoxin system keeps cellular proteins in a reduced state, along 
with glutathione (mycothiol is used in M. tuberculosis).5–7 
Thioredoxins are well-studied proteins, found in all organisms.8 
They share common features such as a conserved catalytic motif of 
WCXXC, and have a low molecular weight of about 12 kDa.9 
Thioredoxins catalyze thiol-disulfide exchange reactions using redox 
active cysteine thiols to reduce oxidized disulfide cysteines of proteins, 
including metabolically essential enzymes.10–12 The oxidized 
thioredoxins are then reduced by thioredoxin reductase (TrxR) in an 
NADPH-dependent reaction, via redox active cysteine or 
selenocysteine thiols, depending on the host organism.13–15 In plants, 
fungi and bacteria, the disulfide reductions in TrxR (~35 kDa) occur 
via a sequence of reactions that begins with hydride transfer from 
NADPH to a bound FAD cofactor, followed by electron transfer from 
FADH2 to the redox-active cysteines, to the thioredoxin, which forms a 
mixed disulfide with TrxR before the thioredoxin cysteines are fully 
oxidized. In higher organisms, such as mammals, the TrxR (~55 kDa) 
transfers the hydride from the NADPH to FAD, then from FADH2 to an 
amino-terminal TrxR active site, then to a carboxy-terminal active site 
of the TrxR/Trx dimer pair. This TrxR/Trx dimer contains a cysteine-
selenocysteine redox-active pair, which then transfers electrons to the 
thioredoxin in a disulfide exchange reaction.14 Thus, the microbial and 
human thioredoxin mechanisms diverge significantly in the steps 
involving Trx binding and reduction. Disruption of this process, by 
selectively targeting the microbe over the host, could be used to kill 
the M. tuberculosis pathogen. Selective targeting should be possible 
since the Trx binding site is in a different region of the TrxR. 
Furthermore, the M. tuberculosis thioredoxins are only 35% identical 
to the human Trx, and the M. tuberculosis TrxR is only 28% identical 
to human TrxR. While these proteins are functionally related from 
microbe to man, the TrxR’s are structurally and mechanistically quite 
different.16,17 
The catalytic cycle of the thioredoxin system from various 
prokaryotic sources has been extensively studied, with the best 
characterized being that from E. coli. The first E. coli Trx solution 
structures were reported over 20 years ago.18–22 Building on this rich 
literature, a comprehensive study from the Ludwig lab23 determined 
structures for the various steps in the E. coli thioredoxin system 
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catalytic cycle, providing a structural complement to the mechanistic 
knowledgebase surrounding the microbial thioredoxin system. While 
the thioredoxin system from E. coli is well characterized, that of M. 
tuberculosis is not.3 Because the E. coli thioredoxin system is so 
similar to that of M. tuberculosis. (TrxR 45% identity, 63% homology, 
and Trx 50% identity and 64% homology), the structural studies 
presented herein build on what has been learned about the E. coli 
system, to provide a foundation for future structure-based design of 
inhibitors that disrupt the M. tuberculosis thioredoxin system, either as 
chemical probes of function, or as potential anti-mycobacterial agents. 
Analysis of structures and models for various steps in the M. 
tuberculosis thioredoxin catalytic cycle, as opposed to individual static 
snapshots of single proteins (ex. TrxR), may suggest novel strategies 
for inhibition. 
The thioredoxin system in M. tuberculosis is comprised of three 
thioredoxins (TrxA, TrxB, and TrxC) and one thioredoxin reductase 
(TrxR).3, 24, 25 It has been shown that M. tuberculosis TrxB and TrxC 
behave as general disulfide reductases with near equal reduction 
potential (−262 mV vs. −269 mV), while TrxA is observed to have only 
a weak capacity to act as a disulfide reductase, and was found to not 
be a substrate for TrxR under the assay conditions tested.3 It has also 
been shown that the ability of M. tuberculosis to survive redox stress, 
while dependent on TrxR, is not dependent on the expression of just 
one thioredoxin. This suggests that having multiple thioredoxins in M. 
tuberculosis may provide a “redundant system” to ensure survival 
under oxidative conditions.3 The thioredoxin system of M. tuberculosis 
is increasingly viewed as a viable drug target for novel anti-
mycobacterials, as long as a drug can be designed that knocks out the 
entire M. tuberculosis thioredoxin system (ex. inhibit TrxR catalytic 
turnover with all Trx’s).26 Of particular interest would be inhibitors that 
remain effective at high levels of competing substrate, either Trx or 
NADPH; this would be uncompetitive inhibition. Cells cannot achieve 
resistance to such uncompetitive inhibitors by increasing levels of 
substrates; but, design of such inhibitors requires structural 
information that enables more than just simple targeting the NADPH or 
Trx pockets on TrxR, as has been the focus to date.17 Design of 
uncompetitive inhibitors requires a knowledge of potential pockets that 
exist during the catalytic cycle and that could be occupied by inhibitors 
(in the presence of Trx substrate), and that stabilize reaction 
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intermediates, thereby stopping catalytic turnover in a manner that 
cannot be overcome at high substrate. Studies presented herein will 
provide structures and models for various steps in the catalytic cycle of 
the M. tuberculosis thioredoxin system to facilitate design of such 
inhibitors. 
Structural studies presented herein focus initially on M. 
tuberculosis TrxC (Fig. 1), and modeling of its interactions with TrxR 
throughout the catalytic cycle, based on NMR chemical shift 
perturbation studies (Fig. 2). While the crystal structure of TrxC in the 
oxidized state has been solved, there is no structure of TrxC in the 
reduced state, and no structural studies of interactions between TrxR 
and TrxC.25 Furthermore, it was previously suggested (but never 
proven) that the crystal structure of TrxC may have had distortions 
due to crystal packing forces that affect the C-terminal helix.25 Studies 
presented herein establish that this is in fact the case. Previous studies 
of the different redox states of prokaryotic thioredoxins have shown 
that there are subtle changes in structure in going from the oxidized to 
the reduced state.22, 27, 28 Most of the changes occur in the active site 
near the redox active cysteines, with some conformational flexibility 
observed in the active site loop.25, 29 Whether this is also true in M. 
tuberculosis TrxC is not known, since there is no structure of reduced 
TrxC. Studies presented herein will provide an analysis of differences 
between reduced and oxidized TrxC. Beyond this, studies will address 
how these forms of TrxC may interact with TrxR at different steps in 
the catalytic cycle (building on the E. coli work from the Ludwig lab), 
and whether these intermediates suggest unique opportunities for the 
design of uncompetitive inhibitors. 
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Figure 1 Solution NMR structures of TrxC: (a) the ensemble for oxidized TrxC with 
a backbone RMSD of 0.54 Å, (b) the ensemble for the reduced state of TrxC with a 
backbone RMSD of 0.50 Å, and (c) overlay of the median structures for both redox 
states, colored as in panels (a) and (b). Note: disordered N- and C-terminal residues 
1–6 and 113–116 have been omitted for clarity in panels (a) and (b). (d) Overlay of 
the median NMR solution structure for the oxidized TrxC (red) and the crystal 
structure of oxidized TrxC (gray), with the active site disulfides shown in yellow. The 
only significant deviation is in the C-terminal helix, α4, which in the crystal structure 
participated in an interaction with another TrxC in the asymmetric unit. 
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Figure 2 2D 1H-15N HSQC spectra of (a) the oxidized state of TrxC (red) with all 
the backbone N-H chemical shifts assigned, and (b) the oxidized (red) and reduced 
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Materials and Methods 
Protein Expression and Purification 
The plasmids containing the Rv3914 gene (TrxC) in the pET22b 
vector and the Rv3913 gene (TrxR) in the pET23a vector were 
obtained from Tuberculosis Vaccine Testing and Research Materials at 
Colorado State University and from Dr. Mande from the Center for DNA 
Fingerprinting and Diagnostics in Hyderabad, India. Both expression 
constructs produced protein with a C-terminal poly-histidine tag 
(Supplementary Figure S4); plasmids were transformed into E. coli 
BL21-(DE3) Rosetta cells from Novagen and grown overnight at 37° C, 
then inoculated into 2 L of LB (Luria Bertani) media supplemented with 
a vitamin mix that included riboflavin (needed for TrxR flavin 
production). Cells containing the TrxR gene were grown until O.D. 600 
nm reached 0.7, at which point cells were induced for 4 hours with 1 
mM IPTG. For expression of TrxC protein cells were grown to 0.7 at 
O.D. 600 at which point the cells were spun down at 7000 rpm and 
washed with M9 minimal media salts (pH 7.0). Cell pellets were 
transferred to 0.5 L of M9 minimal media containing 0.5 grams 15NH4Cl 
and 2.0 grams of 13C-glucose as the only sources of nitrogen and 
carbon, to yield uniformly labeled protein.30 The cells were allowed to 
acclimate for 1 hour and then induced with 1 mM IPTG for an 
additional 4 hours at 37° C, then harvested. The bacterial pellet was 
resuspended in lysis buffer consisting of 50 mM Tris base, 300 mM 
NaCl, 5 mM imidazole, and 10% glycerol at pH of 7.8, and lysed using 
sonication. The lysate was clarified by centrifugation at 15,000 RPM for 
30 minutes and the supernatant loaded onto 1 mL of nickel-Sepharose 
(Amersham Sciences) resin at 1 mL/minute. The bound protein (TrxC 
or TrxR) was then washed with lysate buffer, then with lysate buffer 
containing 25 mM imidazole, and then eluted using lysate buffer 
containing 300 mM imidazole. The eluted protein was than dialyzed 
with 40 mM potassium phosphate buffer at pH of 6.3 (for NMR 
structure studies) and pH of 7.0 (for TrxC/TrxR binding experiments) 
and concentrated to 1 mM using Amicon Ultra-4 centrifugal device 
(Millipore) with protein concentration determined by the absorbance at 
280 nm using extinction coefficients of 11,000 and 14,440 L/mol-cm 
for TrxC and TrxR respectively, based on ProtParam calculations 
(http://expasy.org/tools/protparam.html). While estimation of protein 
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concentration in this manner may slightly overestimate TrxR 
concentration (the FAD has some absorbance at 280 nm), exact 
stoichiometry is not required for titration of TrxC with TrxR, because 
we see complete disappearance of crosspeaks at < 1:1 stoichiometry 
due to exchange broadening. The purpose of the TrxR/TrxC titration is 
simply to identify interface crosspeaks, and the residues corresponding 
to those crosspeaks. Flavin incorporation into TrxR was verified using 
UV-Visible spectroscopy (Supplementary Fig. S5). For studies of 
reduced protein, 5 mM DTT was added. 
NMR Spectroscopy and Structure Calculation 
All NMR experiments were performed on a 600 MHz Varian NMR 
System at 599.515 MHz using a triple resonance cryoprobe with z-axis 
gradients at 25 °C. Backbone assignments were obtained using 2D 1H-
15N HSQC, and 3D HNCO, HN(CA)CO, HNCA, HN(CO)CA, CBCA(CO)NH, 
and HNCACB spectra. Side chains were assigned using CC(CO)NH, 
HBHA(CO)NH, HCC(CO)NH, and HCCH-TOCSY spectra. Distance 
restraints were obtained from 3-D 15N-NOESY, 13C aliphatic NOESY, 
and 13C aromatic NOESY experiments, which were obtained using 150 
ms mixing times. Structures were calculated using these distance 
restraints with the program CYANA,31–33 in conjunction with backbone 
phi and psi angle restraints as predicted from TALOS34 based on 
chemical shifts of Cα, Cβ, Hα, Hβ, HN, and CO atoms. Initial structures 
were obtained using the noeassign macro of CYANA,33 followed by 
manual refinement using the calibration of peaklists by the CYANA 
function caliba, with the disulfide bond added as a restraint for the 
oxidized structure. A final ensemble of 500 structures was calculated, 
and the 100 conformers with the lowest target function were then 
selected for water refinement using AMBER.35 Using implicit solvent, a 
500 step energy minimization was first performed on the 100 
structures (no restraints) followed by two cycles of 30 ps simulated 
annealing from 1000K to 0K, with distance and dihedral restraints 
applied. After the MD simulated annealing, a 2000 step minimization 
with restraints was applied in implicit solvent and analyzed for distance 
and dihedral penalties and rank ordered by lowest AMBER energy. The 
20 lowest energy structures were then selected for the final ensemble 
(Fig. 1), and were analyzed using the Protein Structure Validation 
Software suite.36 NMR spectra were processed using NMRPipe37 and 
analyzed using NMRView38 and Sparky.39 Processing was performed 
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with a cosine bell window function in the direct and indirect 
dimensions. 
Structural Modeling of Intermediates in the M. 
tuberculosis Thioredoxin Reductase Catalytic Cycle 
The M. tuberculosis thioredoxin reductase crystal structure (pdb 
code 2A87)17 had previously been solved in the oxidized state (in what 
is referred to as the FO conformation). To create a model of TrxR in the 
reduced state, where the disulfide is converted to surface free thiols 
(available to react with and reduce thioredoxins), the coordinates of 
the E. coli homolog of TrxR bound to a thioredoxin (pdb code 
1F6M)(40) were used as template. Specifically, the M. tuberculosis 
TrxR (oxidized) structure was superimposed on the E. coli TrxR 
(reduced) structure. But, since the reduced E. coli TrxR is known to 
have a 66° domain rotation relative to the oxidized TrxR,17, 40 this 
same rotation was created in the M. tuberculosis structure. To do this, 
the pdb file of M. tuberculosis TrxR was split at amino acids 117 and 
241 so that the FAD and NADPH domains could be separated. The 
separated NADPH and FAD domain coordinates were then 
superimposed onto the coordinates of the E. coli NADPH and FAD 
domain using Pymol41, then rejoined and then minimized using 
AMBER.35 This yielded what is referred to as the FR conformation. To 
model the various oxidation states of the TrxR/TrxC complexes, 
including the mixed disulfide between TrxR and TrxC, structures were 
minimized with a restrained disulfide bond between the cysteines 
(oxidized) or left with no restraint (reduced). All AMBER minimizations 
were performed with 2000 steps in implicit solvent. 
Thioredoxin System NMR Binding Experiments 
In order to establish which redox states of TrxC, TrxR and 
NADPH/NADP+ interact, and where interacts occur, chemical shift 
perturbations were monitored using 15N-labeled TrxC (reduced or 
oxidized) (Fig. 2). If binding occurs, based upon observation of 
chemical shift changes in HSQC spectra, chemical shifts are mapped 
onto the surface of TrxC to guide and confirm modeling of the 
TrxC/TrxR complexes, described in the previous section. These data 
were used, in part, to construct the models in Fig. 3, as described in 
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Fig. 4 and Supplementary Fig. S2. TrxC and TrxR solutions were 
exchanged into 50 mM potassium phosphate buffer at pH 7.0, then 
concentrated to 1 mM each. TrxC was diluted to 320 μM in the absence 
of DTT, so that it was in the oxidized state. TrxR was then added to 
the TrxC NMR sample, so that both proteins were at equal 
concentrations of 250 μM. NADPH was then added to the sample at 1 
mM so that TrxR would reduce the disulfide of TrxC. As a control to 
test for binding in the presence of the different redox states of the 
cofactor, NADP+ was added to the sample at 1 mM. 1H-15N HSQC 
experiments were acquired after every addition, and pH was measured 
to ensure that it remained at 7.0. As a control for the reduced state, 
1H-15N HSQC spectra were acquired for TrxC in the oxidized state, and 
then reduced by DTT at pH 7.0. 
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Figure 3 The complete redox and catalytic cycle for the M. tuberculosis thioredoxin 
system, modeled after the E. coli thioredoxin catalytic cycle. The cycle begins with free 
TrxR (colored red) in the oxidized state, with bound NADP+, with the first step being 
release of NADP+ and a simple domain rotation to produce the FO conformation. FR and 
FO refer to the reduced or oxidized conformations (not the redox state) of TrxR, which 
are related by a 66° rotation of the NADPH and flavin domains. TrxC (ox and red) 
structures are those reported herein (colored blue), TrxR (FO) is the previously 
reported crystal structure, while models for the various complexes were constructed 
based on structural and functional data for the E. coli thioredoxin system, and 
chemical shift perturbation studies. Expansions show the redox state of relevant thiols 
or disulfides. Each modeled complex was minimized with AMBER. This cycle can also 
be visualized via a molecular animation (Supplementary materials), and structure 
models are available to be used in docking or structure-based drug design efforts. 
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Figure 4 Definition of the TrxR/TrxC interface using chemical shift perturbation 
studies. (a) Several HSQC spectra were overlaid, with blue crosspeaks corresponding 
to free reduced TrxC (in presence of 1 mM DTT). Green crosspeaks correspond to a 
~1:1 complex between TrxC/TrxR at 250 μM (TrxC in slight excess over TrxR), with a 
fourfold excess of NADPH added. In cases where there was exchange broadening due 
to TrxR binding to TrxC, green peaks are no longer visible; so, the presence of blue 
identifies residues that are likely to be at the TrxC/TrxR interface. Orange crosspeaks 
correspond also to the complex between TrxC/TrxR at 250 μM, but now with a four-
fold excess of NADP+ added in addition to 1 mM DTT. The exact match between green 
and orange crosspeaks suggests these two ternary complexes are similar, if not 
identical, and would correspond somewhat to intermediate F (but possibly with the 
mixed disulfide reduced) in Fig. 3. All spectra were acquired at pH 7.0. (b) Interface 
residues, which are largely hydrophobic, are shown as a surface rendering (white). 
This is the interface that forms when TrxR binds to and reduces an oxidized TrxC, and 
includes F142 and F143 on TrxR. (c) Residues on TrxC that show chemical shift 
perturbations or line broadening (from panel (a)) upon binding to TrxR have been 
mapped on the TrxC solution structure as blue Van der Waals spheres. These residues 
define the binding interface with TrxR (in panel (b)). 
Thioredoxin System Interface Inhibition Docking and 
Titration Experiments 
An in-house collection of 10,000 drug-like chemicals was docked 
into open spaces at the interface of the TrxC-TrxR complex using 
Autodock 4.2.42, 43 The grid box was centered at the interface and was 
24.75 Å × 25.5 Å × 29.25 Å. Autodock 4.2 docked each ligand 50 
times, scored the pose based on the program’s force field, and 
clustered each pose based on a root-mean-squared difference from the 
other poses. NMR screening of individual chemicals was prioritized by 
the cluster’s mean binding energy and population. Compounds that 
scored favorably were then dissolved in DMSO to a concnetration of 5 
mM. Binding studies were performed by combining 200 μM TrxC, 250 
μM TrxR, and 0.80 mM NADPH in the NMR buffer described above. 
Compounds were added at 200 μM (DMSO ~4% by volume) and HSQC 
spectra acquired before and after compound addition, and analyzed for 
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Results and Discussion 
NMR Solution Structures of Oxidized and Reduced 
Thioredoxin C 
The solution structures of M. tuberculosis thioredoxin C were 
solved by NMR (Fig. 1), with 2036 NOE derived restraints and 168 
angle restraints in the oxidized state and 2114 NOE restraints in the 
reduced state with 169 angle restraints. Statistics describing the 
restraints used in calculation, precision, and quality of the structures 
are summarized in Table I. The ensemble of structures for oxidized 
TrxC (PDB entry 2L59 and BMRB entry 17268) has a backbone RMSD 
of 0.54 Å, and 0.50 Å for the reduced state (PDB entry 2L4Q and 
BMRB entry 17242), shown in Figs. 1A and 1B. To ensure that the 
cysteines were reduced, 5 mM DTT was added to the protein sample 
and chemical shifts were monitored before and after each experiment, 
using a 1H-15N HSQC (Fig. 2A–B) spectrum. Reduction of the active site 
cysteines results in a decrease in the 13Cβ chemical shifts from 44.6 to 
26.9 ppm and 35.1 to 27.6 ppm for Cys37 and Cys40 respectively, 
consistent with the additional shielding that is present with the 
electron rich thiol, compare to the disulfide. After addition of DTT to 
oxidized TrxC, those residues that are affected the most are located 
along the active site loop, including F32, A34, T35, C37, G38, and 
C40. 
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Table I NMR and water refinement statistics and analysis for solution structures of 
both redox states of Mycobacterium tuberculosis 
Analogous to the situation with the E. coli thioredoxin solution 
structures,18–22 the oxidized and reduced forms of TrxC are very similar 
to each other, showing only small differences between oxidized and 
reduced states, with a pairwise RMSD of only 0.53 Å between the 
ensembles (Fig. 1C). Consistent with other thioredoxins, TrxC in both 
states has the characteristic folding pattern of 4 α-helices surrounding 
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a 5 stranded beta sheet core, consisting of three parallel strands and 
two antiparallel strands. The redox active cysteine residues C37 and 
C40 are located in the conserved active site loop (C37-G-P-C40) that 
leads into the α2 helix, which in both redox states is a bent helix. The 
active site of TrxC includes a predominately hydrophobic core including 
two Ala (34 and 44), two Pro (39 and 81), an Ile (80), and a Val (43) 
residue. Both Trp (33 and 36) indole rings are within 6 Å of the two 
Cys’s, with W36 also forming the interface surface that interacts with 
TrxR (Fig. 4). The disulfide in the oxidized state has the typical 90° χss 
angle for the C-S-S-C linkage. Interestingly, roughly the same 
geometry with the same χss angle is present in the reduced state. The 
most dramatic change in going from oxidized to reduced state is the 
distance between the Cys residue sidechains, with the S-S distance in 
the oxidized state of the median structure in the ensemble having a 
distance of 2.0 Å, compared with 3.5 Å in the reduced state (Fig. 1C). 
That is, overall geometry is roughly the same before and after S-S 
bond formation; but, the thiols move 1.5 Å closer together as the bond 
forms. 
The N-terminal (α1) helix is somewhat irregular, but is nearly 
identical between the two redox states, and is the same as in the 
crystal structure of M. tuberculosis TrxCox25 as well as both E. coli Trx 
solution structures. The α4 helix spans residues 101–111, but begins 
to show fraying at L108. There are some differences between the two 
redox states in the turn region linking the α1 helix to the β3 sheet 
(residues 22–26), and the α3 helix connecting to the β4 sheet 
(residues75–81). The latter region closely contacts the active site 
region. These regions are probably dynamic in nature, and show 
similar effects in the E. coli solution structures of the different redox 
states (Fig. S1). 
Comparison to the M. tuberculosis TrxC Crystal 
Structure 
The M. tuberculosis TrxC crystal structure (pdb code 2i1u)25 was 
solved in the oxidized state, and is nearly identical in secondary 
structure to our solution structure, with a pairwise RMSD of 0.83 Å 
between the crystal structure and the median structure from the 
ensemble (Fig. 1D). But, there is one significant difference – and that 
is with regard to the orientation of the C-terminal α4 helix. It was 
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noted in the crystal structure study that the protein crystals packed 
such that the C-terminus (residues 110–114) in the α4 helix rested in 
the active site groove of an adjacent protein in the crystal lattice, 
which the authors noted could cause a structural perturbation. Based 
on our solution structure of oxidized TrxC, this crystal packing effect 
does in fact seem to have caused the α4 helix to be pushed up 2.7 Å 
towards the β5 strand, and rotated in towards the β4 strand (Fig. 1D). 
Residues 108–115 in the crystal structure are disordered, perhaps so 
that those residues can occupy the active site of a neighboring TrxC 
protein. However, residues 108–111 still retain helical shape (as 
mentioned above) before becoming disordered at residues 112–115 in 
our solution structure. Although it is possible that some difference in 
the α4 helix may stem from the C-terminal histidine tag, we believe 
this is unlikely since the solution structure maintains the characteristic 
thioredoxin folding pattern, and is more compact than the crystal 
structure (Figure S1). Even though the distortion of the α4 helix and 
its ability to participate in a protein-protein interaction may be an 
artifact of crystal packing, its ability to participate in this interaction 
may also hint of a biologically relevant role. That is, since α4 is 
flexible, it is possible that it plays a role in protein-protein interactions 
with TrxR, which may require motion of this helix. In this regard, we 
have also performed calculations of generalized order parameter of 
TrxC, based on the “Random Coil Index”44, and found that several 
active site loop regions are predicted to have low order parameters (S2 
< 0.8), including the loop that leads into the α4 helix (Supplementary 
Fig. S3). Flexibility in these loops may indicate they can function as 
hinges that enable motion of the N- and C-terminal helices α1 and α4, 
to optimally fit into the binding site presented by TrxR. 
Structures and Models of M. tuberculosis Thioredoxin C 
(oxidized and reduced) and Thioredoxin Reductase 
throughout the Thioredoxin Catalytic Cycle 
After having reduced other proteins in the cell, the oxidized TrxC 
must be regenerated to the reduced state by the enzyme thioredoxin 
reductase (TrxR). This process had been thoroughly studied in E. coli, 
culminating in a structural characterization of the various steps in the 
TrxR catalytic cycle.40 Fig. 3 presents the corresponding structures and 
structural models for the M. tuberculosis TrxR/TrxC system in different 
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redox states, depicting the complete redox cycle between TrxR and 
TrxC, using the M. tuberculosis TrxR crystal structure17, our TrxC 
structures (oxidized and reduced), and the various E. coli structures40 
as templates, with protein complexes created or confirmed based on 
chemical shift (and line-width) perturbation studies. Chemical shift 
mapping studies used to create these complexes are summarized in 
Fig. 4 and Supplementary Fig. S2. M. tuberculosis. TrxR is known to 
undergo a large domain rearrangement, to position the reactive 
cysteines so that they are able to react with the disulfide on the 
thioredoxin substrate. The crystal structure of the M. tuberculosis TrxR 
is in the oxidized conformation (FO), with its disulfide buried in the 
protein interior, near the isoalloxazine ring of FADH2; FADH2 provides 
the electrons to reduce this disulfide (step B to C in Fig. 3). The 
reduced state of M. tuberculosis TrxR (FR), with its cysteines now at 
the surface, and the NADPH close to the FAD (D in Fig. 3), was 
modeled using the E. coli thioredoxin reductase structure as a 
template (pdb code 1f6m).40 This structure was used to guide initial 
positioning of the M. tuberculosis TrxR FAD and NADPH domains. In 
this manner, structural models have been created for all the steps in 
the thioredoxin reaction sequence (Fig. 3), using chemical shift 
perturbation data to define the TrxR and TrxC interface (see below). 
NMR Data Defining the Binding Interface between M. 
tuberculosis TrxC and TrxR 
It has previously been proposed that the E. coli TrxR exists in a 
dynamic equilibrium between two conformations (FO and FR),23 
irrespective of the state of oxidation for the flavin or cysteines. It is 
hypothesized that changing redox state or binding to the thioredoxin 
(Trx) substrate merely shifts the FO/FR equilibrium. To determine what 
oxidation state the proteins (TrxC and TrxR) must be in for binding to 
occur, a series of 1H-15N HSQC titration experiments were performed 
so that changes to the state of the proteins in different oxidative 
states could be monitored (Fig. 4; Supplementary Fig. S2). Chemical 
shift changes could be due to binding or to conformational/structural 
changes induced by redox changes; the latter effects are known from 
DTT titrations of isolated TrxC (Fig. 1B). When oxidized TrxR, in the 
absence of NADPH, was added to TrxC, there were no chemical shift 
changes to TrxC (Fig. S2), indicating that oxidized TrxR (that has no 
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NADP(H) cofactor bound) cannot bind to TrxC. Interestingly, a small 
amount of TrxC that was present in a reduced state was converted to 
a fully oxidized state, indicating that even though the oxidized TrxC 
cannot bind, the reduced TrxC can bind to oxidized TrxR (lacking 
NADP(H)) and react in what would be the reverse of the biologically 
relevant direction (high NADPH concentrations ensure the reductive 
reaction is favored in vivo). When the reducing agent (NADPH) for the 
thioredoxin system was added in excess (4-fold), all of the oxidized 
TrxC was converted to the reduced state in the presence of TrxR, via 
the TrxR-catalyzed reduction (Supplementary Fig. S2); this is 
consistent with the reduced TrxR/NADPH being able to bind TrxC. 
While there were no chemical shift differences in comparing the 
TrxR/NADPH-reduced TrxC (TrxR present) with the DTT-reduced TrxC 
(TrxR absent), the presence of TrxR did cause disappearance of some 
TrxC crosspeaks due to exchange broadening (see below). This 
exchange broadening identifies residues at the TrxR/TrxC interface, 
thereby facilitating construction of properly docked TrxR/TrxC models 
(Fig. 3). 
When the spectra for the TrxC/TrxR mixture, which has been 
reduced using NADPH or DTT (+ NADP+), were overlaid (Fig. 4), there 
were again no distinguishable chemical shift changes. When compared 
to the spectrum for unbound TrxC (reduced), there are a number of 
residues that disappear due to exchange broadening, due to binding 
interactions between TrxC and TrxR. The residues that showed 
exchange broadening were mapped onto the reduced state solution 
structure of TrxC in Fig. 4. The majority of these residues are in the 
active site region of the protein (F32, A34, T35, W36, C37, T67, V78), 
and these residues create a hydrophobic surface that interacts with 
TrxR, and that was used to define the protein-protein interface region 
for constructing the structural models in Fig. 3. Based on these results, 
although TrxR may be sampling both FO and FR states, TrxC will only 
bind to the reduced (free thiol) form of TrxR with cofactor (NADPH) 
bound, not to the FO state that is lacking NADPH cofactor. 
Analysis of the M. tuberculosis Thioredoxin Cycle 
Models 
As illustrated in Fig. 3, and by analogy to the E. coli system, the 
catalytic cycle for the M. tuberculosis thioredoxin system is shown 
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starting in the conformation described as “FR” (intermediate A in Fig. 
3), so that the active site cysteines have just finished reducing TrxC 
(which was released in the previous step), and there are bound NADP+ 
and FADH2 cofactors. It is called the FR state because of the relative 
orientation of the NADPH and FAD domains such that the NADPH 
binding site is close to the FAD (and the thiol/disulfide is distal). 
Assuming M. tuberculosis TrxR behaves as the E. coli reductase, it will 
then undergo a 66° rotation around the NADPH binding domain to 
bring the disulfide bonded cysteines (C145 and C148) proximal to the 
isoalloxazine ring of FADH2, while the NADPH binding pocket moves 
away from the FADH2, thereby allowing NADP+ to be released (this 
creates intermediate B). This also positions the isoalloxazine ring of 
FADH2 to within 3.7 Å of the S atom of Cys148 (now TrxR is in the “FO” 
state), which permits electron transfer from flavin to the disulfide 
(transfer will most likely be to the more proximal cysteine, Cys148). 
After the FADH2 reduces the disulfide, the sulfur inter-atomic distance 
increases from 2.0 Å to 3.7 Å, giving a slightly smaller χ angle across 
what was the disulfide. After reduction, a general base (likely to be 
D149, which is 5.3 Å from the thiol of C148) abstracts a proton from 
C148 to produce a thiolate that is ready to attack the disulfide of the 
thioredoxin (intermediate C converted to D).45 NADPH then binds to 
TrxR, and the NADPH domain undergoes another 66° rotation to bring 
the reduced active site cysteines away from the FAD isoalloxazine ring, 
and back to the surface (back to the FR conformation) of the protein, 
core that defines the TrxC binding pocket (the concave pocket on the 
bottom of intermediate D in Fig. 3). Elsewhere in the protein in 
intermediate D, the NADPH nicotinamide ring comes to within 3.4 Å of 
the isoalloxazine ring of FAD so that it can reduce the N5 position of 
FAD, again producing FADH2. The FADH2 can once again reduce the 
disulfide of TrxR, later in the catalytic cycle. 
The TrxR is now in a conformation that can bind and then 
reduce TrxC (intermediate E). Inspection of this TrxC/TrxR structural 
model reveals that helix a4 is in contact with the mobile NADP(H) 
domain of TrxR (the α4 helix is on the far left side of the blue TrxC, as 
shown in Fig. 3, intermediates E–G). This same α4 helix was distorted 
in the crystal structure of TrxC, and is attached to the core TrxC 
structure via a flexible linker (predicted S2 < 0.8; Supplementary Fig. 
S3) based on our solution NMR studies. It appears that this mobile α4 
helix permits binding of TrxC to the TrxR FR state (the FO state can’t 
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bind Trx, because it has this TrxR interface rotated 66° away). Also of 
interest is that the α1 helix, which is likewise attached to the TrxC core 
via a flexible linker, makes contact on the opposite side of the TrxR 
pocket; and, the distortion (kink) in helixα1 creates a somewhat 
convex surface that may be essential for matching the concave shape 
of the TrxR pocket (the far right side of the blue TrxC structure in 
intermediate E of Fig. 3). Thus, a majority of the TrxR/TrxC binding 
interface is comprised of the α1 and α2 helices, which form a convex 
recognition surface on TrxC. 
In addition to TrxR interactions with the TrxC α1 and α4 helices, 
the complex appears to be stabilized by a hydrophobic interface 
produced in the FR state by TrxR residues F142 and F143, which 
interacts with TrxC residues A34, P39, V43, A44, A72, V78, I80, and 
P81. Fig. 4 shows a view of the binding interface between TrxR and 
TrxC, identified using chemical shift mapping, with surface rendering 
showing the hydrophobic pocket. Of particular interest is that W36 of 
TrxC, which is conserved in all thioredoxins. W36 has its indole ring 
situated in this hydrophobic pocket, with the ring NH hydrogen 
bonding to the carboxyl group of Asp66, at a distance of 1.9 Å. This 
interaction is likely to be important for proper positioning of the TrxC 
C37, for reaction with the TrxR thiol/disulfide (C145, C148). The 
thiolate of C148 in TrxR is 4.9 Å from the disulfide-linked cysteine thiol 
(C37) of TrxC (intermediate E). Attack of C37 on C148 (disulfide) 
would produce the mixed disulfide between the two proteins 
(intermediate F), which is analogous to the mixed disulfide structure of 
E. coli TrxR/Trx that was structurally characterized by the Ludwig 
group.40 The free thiolate in TrxR (Cys145) then attacks Cys148 of the 
mixed disulfide, thereby producing fully reduced TrxC in the thiol 
reduced state (intermediate G). The newly reduced TrxC is released 
from the now oxidized TrxR, which is in the same state as Fig. 4A, 
thereby completing the thioredoxin catalytic cycle. The structural 
changes associated with this catalytic cycle can also be viewed as a 
molecular animation that was created using PyMol (supplementary 
materials). This series of thiol/disulfide exchanges is distinct from, and 
occurs in a different active site region, in the mammalian thioredoxin 
system. Accordingly, targeting this active site region in drug design 
efforts could provide compounds that are specific for microbial over 
mammalian enzymes. 
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Developing an inhibitor that targets the M. tuberculosis. 
thioredoxin system rather than the human thioredoxin system would 
provide a novel route to anti-mycobacterial drugs. The function of the 
thioredoxin system, from microbe to man, is to maintain redox 
homeostasis by keeping cellular proteins reduced; and, in doing this, 
Trx becomes oxidized, so must be reduced by TrxR. The M. 
tuberculosis. TrxR undergoes a domain rotation in to move the NADPH 
and FAD(H2) in proximity to each other, and to move the reduced 
active site cysteines proximal to bound Trx.17 The human thioredoxin 
reductase instead uses a cysteine-selenocysteine active site on a 
flexible carboxy-terminal tail that is absent in the microbial enzyme, to 
shuttle FAD(H2) electrons to its bound thioredoxin (Figure 5B).14 In 
comparing the models from M. tuberculosis., described herein, and the 
recently published human thioredoxin system16, it becomes clear that 
there are significance structural differences (Fig. 5), along with the 
mechanistic differences, that can be exploited for selective inhibition of 
the microbial system. The human thioredoxin reductase has an 
additional domain that interacts with Trx (Fig. 6, interface domain, Fig. 
5B and 5C), that is absent in the microbial system. Furthermore, the 
active site cysteines (that receive electrons from FADH2) are not 
directly exposed to the bound Trx, as they are in the microbial system. 
Of particular importance is the absence of the binding pocket between 
the Trx and TrxR that was observed in M. tuberculosis complex 
(compare Figs. 3B and and5B),5B), because the human system uses 
the C-terminal domain for the final electron transfer step to bound Trx. 
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Figure 5 Comparison of the M. tuberculosis. and human Trx-TrxR complex. (a) M. 
tuberculosis. Trx (blue)-TrxR (red) mixed disulfide. (b) Human Trx (orange)-TrxR 
(teal) mixed disulfide. Note the carboxy-terminus of the dimer pair is highlighted in 
violet and forms the mixed disulfide. (c) Overlay of the M. tuberculosis. and human 
thioredoxin systems. (d) Close up of M. tuberculosis thioredoxin complex disulfide 
from Figure 5(c). (e) Close up of the human thioredoxin complex disulfide from Figure 
5(c). 
 
Figure 6 Comparison of the three thioredoxin reductases discussed in this study. 
The M. tuberculosis. TrxR shows 45% identity and 63% homology to the E. coli TrxR 
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and 14% identity and 22% homology to human TrxR1. ○ denotes active site cysteines. 
∅ denotes cysteines that form mixed disulfides between the thioredoxin and 
thioredoxin reductase. ⊙ denotes the selenocysteine from human thioredoxin 
reductase. 
Besides providing insights into mechanism, and providing 
structural hypotheses that can be tested with future mechanistic 
studies (ex. using site-directed mutagenesis), the models presented 
herein (Fig. 3) can be used to facilitate structure-based design of 
inhibitors that selectively block the M. tuberculosis thioredoxin 
catalytic cycle, by targeting the Trx/TrxR interface. While inhibitors 
could be designed to block either the NADP(H) or TrxC substrate 
pockets on TrxR, the former class would yield inhibitors that might not 
be selective for the microbial system and which would be competitive 
versus cofactor. The latter approach is attractive, but suffers from the 
usual challenge of finding inhibitors that bind to broad protein-protein 
recognition surfaces; and, competitive inhibition can be overcome by 
the pathogen increasing expression levels of TrxC. A third approach 
might be to design inhibitors that occupy pockets that appear in the 
catalytic cycle at the Trx/TrxR interface, and are present even when 
Trx substrate is bound, so that binding of an inhibitor might stabilize 
that intermediate in the presence of substrate and thereby block 
catalytic turnover. This is the general concept behind uncompetitive 
inhibition. To illustrate the feasibility of the strategy of targeting 
interface pockets, a library of 10,000 compounds was docked into a 
pocket that is present in intermediates E, F and G (Fig. 3), at the 
interface of TrxR and TrxC. Compounds with reasonable drug-like 
appearance and properties (ex. adherence to Lipinski Rule of 5) are 
found that fit into this pocket (Fig. 7). Initial characterization of one of 
these compounds, by titrating onto the TrxR/TrxC complex, has shown 
some cross-peak perturbations, including the NH of interface residue 
W33. This result suggests feasibility of identifying compounds that 
bind at the TrxR/TrxC interface. More in-depth studies are needed to 
fully characterize the potential druggability of this binding site, by 
identifying and characterizing multiple inhibitors and establishing 
structure-activity relationships for binding at the TrxR/TrxC interface. 
These studies should include verification of binding by multiple 
techniques (direct binding and enzyme activity measurements), as well 
as MIC measurements, first in a model organism (ex. M. smegmatis) 
and ultimately in M. tuberculosis. Such structure-based drug design 
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efforts are enabled by the results we have presented here, and are 
currently underway. 
 
Figure 7 (a) Result of docking into one of the intermediates in the thioredoxin 
catalytic cycle, to demonstrate the presence of potential binding pockets at the 
Trx/TrxR interface of sufficient size to accommodate potential inhibitors or drug leads. 
After docking 10,000 compounds, the best scoring (lowest energy) docked structure 
(shown in green, compound number CSDDD_6702) occupied a site at the interface of 
TrxR (red) and TrxC (blue) in Panels A and B, with energy = −10 kcal/mol using 
AutoDock4. (b) Expansion that shows the docking pose for CSDDD_6702. (c) 
Expansion showing the crosspeak perturbations in a section of the 15N-1H HSQC upon 
addition of 200 μM of compound CSDDD_6702 (blue) to a sample containing 200 μM 
TrxC, 250 μM TrxR, and 0.80 mM NADPH (black). Interface residue W33(HE1) is 
represented by the crosspeak at 10.2 ppm, which has been shifted upon binding 
CSDDD-6702. 
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In summary, we have determined high-resolution solution 
structures for both redox states of thioredoxin C (TrxC) from M. 
tuberculosis using NMR (backbone RMSD of 0.54 and 0.50 Å for TrxCox 
and TrxCred, respectively). The secondary structure and folding of the 
oxidized and reduced states of TrxC are nearly identical, with only 
subtle changes around the active site cysteines, and with some 
changes in loop regions. In the presence of the TrxR from M. 
tuberculosis, it appears that TrxC binds to TrxR only when TrxR has a 
reduced disulfide and cofactor (NADP(H)) bound. This was 
demonstrated by the disappearance of cross peaks for residues in the 
active site of TrxC, due to exchange broadening. The lack of other 
chemical shift changes (or peak shape changes) suggests that there 
are no significant structural changes to TrxC upon binding to TrxR. 
Using our structures and chemical shift perturbation data, along with 
the previously reported TrxR structure and structures for the 
thioredoxin system from E. coli,40 we constructed structural models for 
all the steps of the catalytic cycle of the M. tuberculosis thioredoxin 
system (Fig. 3). These structures, significantly different from the 
human thioredoxin system, should facilitate future mechanistic studies 
of the M. tuberculosis thioredoxin system, and aid in the design of 
inhibitors as potential drug leads. Indeed, initial analysis of these 
structures have identified at least one potential binding pocket, which 
is distinct from both substrate pockets, that could be pursued in 
structure-based drug design efforts. Inhibitors of the M. tuberculosis 
thioredoxin system may serve as chemical probes to study this 
pathogen’s ability to survive intracellular redox stress, in addition to 
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Figure S1. Overlays of both redox states of solution structures from E. coli Trx 
and M. tuberculosis TrxC, where A) is the overlay for the oxidized states, with blue 
being from M. tuberculosis and green from E. coli and B) is the overlay for the reduced 
states, with wheat being from M. tb and purple from E. coli. 
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Figure S2. 2D 1H-15N HSQC spectra where the black cross peaks in all panels are 
for oxidized/reduced TrxC and A) TrxR has been added to the sample (red), B) TrxR 
has been added to the sample and the redox activity initiated by addition of with 
NADPH to reduce TrxC (green), and C) DTT is added to the sample to fully reduce TrxC 
as a control experiment (blue). Protein concentration is 250 μM for TrxC and TrxR is 
slightly less than 250 μM. 
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Figure S2 continued. 2D 1H-15N HSQC spectra where D) black cross peaks 
are for oxidized/reduced TrxC and TrxR is added to the sample along with the oxidized 
cofactor NADP+. E) The overlay of the DTT reduced sample (blue) and the NADPH 
reduced sample (green), and F) is the same as panel E with the oxidized sample from 
panel D and DTT added to it (orange). 
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Figure S3. Top panel: Calculated order parameters, based on the Random Coil 
Index (RCI), from the Wishart group. Bottom panel: structure of TrxC (reduced) 
showing those segments (in red) with the greatest disorder, predicted to be random 
coil. The α1 and α4 helices are shown on the left and right sides, respectively, in the 
above representation. 
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Figure S4. Structure of TrxC showing location of last contiguously assigned 
residue, Asn116. The C-terminal histidine tag was present after Asn116 (some 
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Figure S5. Absorbance spectrum of a TrxR sample (28 μM) at 25 degrees in a 50 
mM phosphate buffer at pH 7.6, obtained using an HP 8452 diode array UV-Vis 
spectrophotometer. Relative band intensity and shape matches that which was 
previously reported for the E. coli thioredoxins (Prongay, A.J., Engelke, D.R., and 
Williams, C.H., Jr. (1989) J. Biol. Chem. 264, 2656-2664). 
 
Figure S6. Physical model of the TrxR/TrxC structural that was built with students 
from Messmer High School (Giovanni Rodriguez, Kevonna Nathaniel, Anwuri Osademe 
and David Gonzalez), and their teacher Carol Johnson, to introduce students to 
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structural biology research. This then led to production of a molecular animation of the 
TrxR/TrxC catalytic cycle in partnership with Milwaukee School of Engineering, as a 
teaching tool (under the NSF-funded CReST program). 
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HSQC heronuclear single quantum coherence spectroscopy 
IPTG isopropyl β-D-1-thiogalactopyranoside 
LB Luria Bertani 
MD molecular dynamics 
NOESY nuclear Overhauser effect spectroscopy 
RMSD root mean square deviation 
Trx Thioredoxin 
TrxR Thioredoxin reductase 
TOCSY total correlation spectroscopy 
Tris tris(hydroxymethyl)aminomethane, NAD 
NAD nicotinamide adenine dinucleotide 
FAD flavin adenine dinucleotide. 
 
References 
1. World Health Organization. Global tuberculosis control: A short update to 
the 2009 report. 2009.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Proteins, Vol. 81, No. 4 (April 2013): pg. 675-689. DOI. This article is © Wiley and permission has been granted for this 
version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Wiley. 
35 
 
2. Jasmer RM, Nahid P, Hopewell PC. Latent Tuberculosis Infection. N Engl J 
Med. 2002;347:1860–1866.  
3. Akif M, Khare G, Tyagi AK, Mande SC, Sardesai AA. Functional studies of 
multiple thioredoxins from Mycobacterium tuberculosis. J Bacteriol. 
2008;190:7087–7095.  
4. Shinnick TM, King CH, Quinn FD. Molecular Biology, Virulence, and 
Pathogenicity of Mycobacteria. Am J Med Sci. 1995;309:92–98.  
5. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. 
Antioxid Redox Signal. 2000;2:811–820.  
6. Arnér ESJ, Holmgren A. Physiological functions of thioredoxin and 
thioredoxin reductase. Eur J Biochem. 2000;267:6102–6109.  
7. Attarian R, Bennie C, Bach H, Av-Gay YG. Glutathione disulfide and S-
nitrosoglutathione detoxification by Mycobacterium tuberculosis 
thioredoxin system. FEBS Letters. 2009;19:3215–3220.  
8. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:237–271.  
9. Martin JL. Thioredoxin-a fold for all reasons. Structure. 1995;3:245–250.  
10. Gleason FK, Holmgren A. Thioredoxin and related proteins in procaryotes. 
FEMS Microbiol Lett. 1998;54:271–297.  
11. Ortenberg R, Gon S, Porat A, Beckwith J. Interactions of glutaredoxins, 
ribonucleotide reductase, and components of the DNA replication 
system of Escherichia coli. Proc Natl Acad Sci U S A. 2004;101:7439–
7444.  
12. Powis G, Briehl M, Oblong J. Redox signalling and the control of cell 
growth and death. Pharmacol Ther. 1995;68:149–173.  
13. Williams CH, Arscott LD, Müller S, Lennon BW, Ludwig ML, Wang P, Veine 
DM, Becker K, Schirmer RH. Thioredoxin reductase. Eur J Biochem. 
2000;267:6110–6117.  
14. Zhong L, Arner ESJ, Holmgren A. Structure and mechanism of mammalian 
thoredoxin reductase: The active site is a redox-active 
selenolthiol/selenenylsulfide formed from the conserved cysteine-
selenocysteine sequence. Proc Natl Acad Sci U S A. 2000;97:5854–
5859.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Proteins, Vol. 81, No. 4 (April 2013): pg. 675-689. DOI. This article is © Wiley and permission has been granted for this 
version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Wiley. 
36 
 
15. Gromer S, Urig S, Becker K. The Thioredoxin System--From Science to 
Clinic. Med Res Rev. 2004;1:40–89.  
16. Fritz-Wolf K, Kehr S, Stumpf M, Rahlfs S, Becker K. Crystal structure of 
the human thioredoxin reductase-thioredxin complex. Nat Commun. 
2011;2:1–8. 
17. Akif M, Suhre K, Verma C, Mande SC. Conformational flexibility of 
Mycobacterium tuberculosis thioredoxin reductase: crystal structure 
and normal-mode analysis. Acta Crystallogr D Biol Crystallogr. 
2005;61:1603–1611.  
18. Dyson HJ, Holmgren A, Wright PE. Structural differences between oxidized 
and reduced thioredoxin monitored by two-dimensional 1H NMR 
spectroscopy. FEBS Lett. 1988;228:254–258.  
19. Dyson HJ, Holmgren A, Wright PE. Assignment of the proton NMR 
spectrum of reduced and oxidized thioredoxin: sequence-specific 
assignments, secondary structure, and global fold. Biochemistry. 
1989;28:7074–7087 
20. Dyson HJ, Gippert GP, Case DA, Holmgren A, Wright PE. Three-
dimensional solution structure of the reduced form of Escherichia coli 
thioredoxin determined by nuclear magnetic resonance spectroscopy. 
Biochemistry. 1990;29:4129–4136.  
21. Forman-Kay J, Clore GM, Wingfield PT, Gronenborn AM. High-resolution 
three-dimensional structure of reduced recombinant human 
thioredoxin in solution. Biochemistry. 1991;30:2685–2698.  
22. Jeng M, Campbell AP, Begley T, Holmgren A, Case DA, Wright PE, Dyson 
HJ. High-resolution solution structures of oxidized and reduced 
Escherichia coli thioredoxin. Structure. 1994;2:853–868.  
23. Lennon BW, Williams CH. Reductive Half-Reaction of Thioredoxin 
Reductase from Escherichia coli. Biochemistry. 1997;36:9464–9477.  
24. Akif M, Chauhan R, Mande SC. Expression, purification, crystallization and 
preliminary X-ray crystallographic studies of Mycobacterium 
tuberculosis thioredoxin reductase. Acta Crystallogr D Biol Crystallogr. 
2004;60:777–779.  
25. Hall G, Shah M, McEwan PA, Laughton C, Stevens M, Westwell A, Emsley 
J. Structure of Mycobacterium tuberculosis thioredoxin C. Acta 
Crystallogr D Biol Crystallogr. 2006;62:1453–1457.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Proteins, Vol. 81, No. 4 (April 2013): pg. 675-689. DOI. This article is © Wiley and permission has been granted for this 
version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Wiley. 
37 
 
26. Zhang Z, Hillas PJ, Ortiz de Montellano PR. Reduction of Peroxides and 
Dinitrobenzenes by Mycobacterium tuberculosis Thioredoxin and 
Thioredoxin Reductase. Arch Biochem Biophys. 1999;363:19–26.  
27. Weichsel A, Gasdaska JR, Powis G, Montfort WR. Crystal structures of 
reduced, oxidized, and mutated human thioredoxins: evidence for a 
regulatory homodimer. Structure. 1996;4:735–751.  
28. Qin J, Clore GM, Gronenborn AM. The high-resolution three-dimensional 
solution structures of the oxidized and reduced states of human 
thioredoxin. Structure. 1994;2:503–522.  
29. Peterson FC, Lytle BL, Sampath S, Vinarov D, Tyler E, Shahan M, Markley 
JL, Volkman BF. Solution structure of thioredoxin h1 from Arabidopsis 
thaliana. Protein Science. 2005;14:2195–2200.  
30. Marley J, Lu M, Bracken C. A method for efficient isotopic labeling of 
recombinant proteins. J Biomol NMR. 2001;20:71–75.  
31. Güntert P, Braun W, Wüthrich K. Efficient computation of three-
dimensional protein structures in solution from nuclear magnetic 
resonance data using the program DIANA and the supporting 
programs CALIBA, HABAS and GLOMSA. J Mol Biol. 1991;217:517–
530.  
32. Güntert P, Mumenthaler C, Wüthrich K. Torsion angle dynamics for NMR 
structure calculation with the new program D. J Mol Biol. 
1997;273:283–298. [ 
33. Herrmann T, Güntert P, Wüthrich K. Protein NMR Structure Determination 
with Automated NOE Assignment Using the New Software CANDID and 
the Torsion Angle Dynamics Algorithm DYANA. J Mol Biol. 
2002;319:209–227.  
34. Shen Y, Delaglio F, Cornilescu G, Bax A. TALOS+: a hybrid method for 
predicting protein backbone torsion angles from NMR chemical shifts. J 
Biomol NMR. 2009;4:213–223.  
35. Case DA, Darden TA, Cheatham ITE, Simmerling CL, Wang J, Duke RE, 
Luo R, Walker RC, Zhang W, Merz KM, Roberts B, Hayik S, Roitberg A, 
Seabra G, Swails J, Goetz AW, Kolossvai I, Wong KF, Paesani F, 
Vanicek J, Wolf RM, Liu J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, 
Cai Q, Ye X, Wang J, Hsieh M, Cui G, Roe DR, Mathews DH, Seetin MG, 
Salomon-Ferrer R, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Proteins, Vol. 81, No. 4 (April 2013): pg. 675-689. DOI. This article is © Wiley and permission has been granted for this 
version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Wiley. 
38 
 
A, Kollman PA. Amber 11. University of California; San Francisco: 
2010.  
36. Bhattacharya A, Tejero R, Montelione GT. Evaluating Protein Structures 
Determined by Structural Genomics Consortia. Proteins: Struct Funct 
Bioinf. 2007;66:778–795.  
37. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a 
multidimensional spectral processing system based on UNIX pipes. J 
Biomol NMR. 1995;6:277–293.  
38. Johnson BA, Blevins RA. NMRView: A computer program for the 
visualization and analysis of NMR data. J Biomol NMR. 1994;4:603–
614.  
39. Goddard TD, Kneller DG. SPARKY 3. University of California; San 
Francisco:  
40. Lennon BW, Williams CH, Ludwig ML. Twists in Catalysis: Alternating 
Conformations of Escherichia coli Thioredoxin Reductase. Science. 
2000;289:1190–1194.  
41. The PyMOL Molecular Graphics System, Version 1.2.r3pre. Schrödinger, 
INC;  
42. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson 
AJ. Automated docking using a Lamarckian genetic algorithm and an 
empirical binding free energy function. J Comput Chem. 
1998;19:1639–1662. 
43. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, 
Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with 
selective receptor flexibility. J Comput Chem. 2009;30:2785–2791.  
44. Berjanskii MV, Wishart DS. A simple method to predict protein flexibility 
using secondary chemical shifts. J Am Chem Soc. 2005;127:14970–
14971.  
45. Veine DM, Mulrooney SB, Wang P, Williams CH. Formation and properties 
of mixed disulfides between thioredoxin reductase from Escherichia 
coli and thioredoxin: Evidence that cysteine-138 functions to initiate 
dithiol-disulfide interchange and to accept the reducing equivalent 
from reduced flavin. Protein Science. 1998;7:1441–1450.  
 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Proteins, Vol. 81, No. 4 (April 2013): pg. 675-689. DOI. This article is © Wiley and permission has been granted for this 
version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from Wiley. 
39 
 
About the Authors 
Daniel S. Sem :  Department of Pharmaceutical Sciences, Concordia 
University Wisconsin, 12800 N. Lake Shore Dr., Mequon, WI 
53097. 
                         Email: Daniel.sem@cuw.edu 
 
